|Articles|August 31, 2006
Hydralazine HCl Injection Recalled
Luitpold Pharmaceuticals, Inc. recalled several lots of Hydralazine HCl Injection (20 mg/mL, 1-mL single-dose vials), labeled with the "Novaplus" label, because the products contain particulates.
Advertisement
Luitpold Pharmaceuticals, Inc. recalled several lots of Hydralazine HCl Injection (20 mg/mL, 1-mL single-dose vials), labeled with the “Novaplus” label, because the products contain particulates. (Aug. 3 and Aug. 25). For more information, see:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet
2
Top 10 BioPharm International Articles of 2025
3
FAQ: Understanding Biosimilars, Biobetters, and Interchangeability
4
Integrated Platform Eliminates Ex-Vivo Expansion Barrier for CAR-T Access
5
